PHARMA MAR, S.A.
Patent Owner
Stats
- 38 US PATENTS IN FORCE
- 1 US APPLICATIONS PENDING
- Nov 28, 2017 most recent publication
Details
- 38 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 938 Total Citation Count
- Sep 09, 1993 Earliest Filing
- 74 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9192568 Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds for treating proliferative diseasesOct 30, 06Nov 24, 15[A61K, A61P]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2011/0213,000 N-(2-THIAZOLYL)-AMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES AND CARDIOVASCULAR DISEASESAbandonedAug 01, 08Sep 01, 11[A61K, C07D, A61P]
2011/0070,232 Combination Therapy with an Antitumor AlkaloidAbandonedMay 18, 09Mar 24, 11[A61K, A61P]
2010/0267,732 Prognostic Molecular Markers for ET-743 TreatmentAbandonedOct 20, 08Oct 21, 10[A61K, C12Q, A61P]
7772241 Variolin derivatives and their use as antitumor agentsExpiredJan 07, 09Aug 10, 10[A61K, C07D]
7767659 Synthesis of naturally occurring ecteinascidins and related compoundsExpiredFeb 04, 03Aug 03, 10[A61K, A01N, C07D]
7723068 Gene cluster involved in safracin biosynthesis and its uses for genetic engineeringExpiredDec 19, 03May 25, 10[C12P]
2010/0041,594 Use of Aplidine for the Treatment of Pancreatic CancerAbandonedOct 23, 09Feb 18, 10[A61K, A61P]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
